Efficacy
NSCLC, SCLC, SD, Tumor
SCLC, TUMOR, DISEASE, UROTHELIAL CARCINOMA, SMALL CELL LUNG CANCER, NSCLC
Of patients receiving itacitinib plus pembrolizumab in Part 1, 4 (8.2%) had partial response (PR) and 19 (38.8%) had stable disease (SD; Tumor response by RECIST (full analysis set)Abbreviations: CI, confidence interval; NSCLC, non–small cell lung cancer; ORR, objective response rate; Q3W, every 3 weeks; QD, once daily; SCLC, small cell lung cancer; UC, urothelial carcinoma.







Of patients receiving parsaclisib plus pembrolizumab in Part 1, 5 (6.0%) had complete response (CR), 9 (10.8%) had PR, and 21 (25.3%) had SD (Of patients receiving parsaclisib plus pembrolizumab in Part 2 of the study, 5 (18.5%) had PR and 6 (22.2%) had SD (